An interventional study of Plain Kefir and Individualized Medical Nutrition Therapy in Obesity & Overweight, Gut Microbiota and Body Composition, sponsored by Pınar Göbel. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Pınar Göbel · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 91 under way, 16 of them phase 3. Obesity · Turkey.
Among the 353 studies in Obesity with a site in Turkey, this one is the 92nd largest by enrollment of the 192 interventional ones that give a count, is one of 38 that started in 2024, is one of 161 with no phase, and was the 335th registered.
11,529 studies on the registry are indexed under Obesity; 2,035 are open to participants now.
Browse Obesity studies →73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Gazi University · Sites in Turkey
Ages 50–60 · Women only
Duzce University · Sites in Turkey
Ages 18+
Pamukkale University · Sites in Turkey
Ages 18–60 · Women only
Kocaeli University · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 166 take children under 18; 488 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 3
First in 2005; this study’s year is marked. 38 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is close to the median of 67 across 9,010 interventional studies indexed under Obesity.
Median enrollment 64 across the 192 interventional studies, 82 across the 160 observational. Of the 236 that completed or were terminated, 7 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 353 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Pınar Göbel as lead sponsor.
Pınar Göbel has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
35 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07936877Mudanya UniversityIntragastric Balloon and Time-Restricted Eating for Weight Loss in Adults With Overweight or Obesity | 2026-11-15 |
| NCT07878299Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyComparison of Segmental Body Composition Characteristics in Lipedema and Obesity | 2026-11-20 |
Add all 35 to your calendar (.ics) → With an account.
Among the 353 studies in Obesity with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study evaluated the effects of daily kefir consumption as an adjunct to medical nutrition therapy on body composition, biochemical parameters, gastrointestinal symptoms, bowel habits, and psychological well-being in women with obesity. Participants were randomly assigned to receive either 200 mL of plain kefir daily together with individualized medical nutrition therapy or individualized medical nutrition therapy alone for 12 weeks. Assessments were performed at baseline, week 6, and week 12. The primary outcome was change in body weight. Secondary outcomes included changes in body composition, biochemical parameters, gastrointestinal symptoms, bowel habits, and psychological well-being.
This study was designed as a randomized, parallel-group, controlled clinical trial to evaluate the effects of daily kefir consumption as an adjunct to individualized medical nutrition therapy in women with obesity. Participants were randomly assigned to one of two intervention groups: (1) individualized medical nutrition therapy plus 200 mL of plain kefir consumed daily, or (2) individualized medical nutrition therapy alone. Both interventions were continued for 12 weeks.
Participants were assessed at baseline, week 6, and week 12. The primary outcome was change in body weight. Secondary outcomes included changes in body mass index, body fat mass, muscle mass, biochemical parameters (fasting blood glucose, lipid profile, liver function tests, and related metabolic markers), gastrointestinal symptoms, bowel habits, stool characteristics, and psychological well-being.
The study aimed to investigate whether the addition of daily kefir consumption to individualized medical nutrition therapy could provide additional benefits beyond diet therapy alone for improving obesity-related health outcomes in women.
The criteria were revised on the registry on Oct 16, 2026. See what changed
nclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received individualized medical nutrition therapy together with 200 mL/day of plain kefir for 12 weeks.
Dietary Supplement: Plain Kefir · Behavioral: Individualized Medical Nutrition Therapy
Participants received individualized medical nutrition therapy alone for 12 weeks.
Behavioral: Individualized Medical Nutrition Therapy
Participants consumed 200 mL of plain kefir daily for 12 weeks in addition to individualized medical nutrition therapy.
Participants received individualized medical nutrition therapy delivered by a registered dietitian throughout the 12-week intervention period.
Change in body weight (kg) from baseline to week 12
Body weight was measured in kilograms using a calibrated digital scale. The primary outcome was the change in body weight from baseline to week 12.
Time frame: Baseline and week 12
Change in body mass index (kg/m²)
Body mass index was calculated as weight in kilograms divided by height in meters squared. The change from baseline to week 12 was evaluated.
Time frame: Baseline and week 12
Change in body fat percentage
Body fat percentage was assessed using bioelectrical impedance analysis.
Time frame: Baseline and week 12
Change in fat mass (kg)
Fat mass was assessed using bioelectrical impedance analysis.
Time frame: Baseline and week 12
Change in muscle mass (kg)
Muscle mass was assessed using bioelectrical impedance analysis.
Time frame: Baseline and week 12
Change in visceral fat level
Visceral fat level was assessed using bioelectrical impedance analysis.
Time frame: Baseline and week 12
Change in fasting blood glucose (mg/dL)
Fasting blood glucose was measured in mg/dL. The change from baseline to week 12 was evaluated.
Time frame: Baseline and week 12
Change in fasting insulin (µIU/mL)
Fasting insulin concentration was measured in µIU/mL. The change from baseline to week 12 was evaluated.
Time frame: Baseline and week 12
Change in total cholesterol (mg/dL)
Total cholesterol concentration was measured in mg/dL. The change from baseline to week 12 was evaluated.
Time frame: Baseline and week 12
Change in LDL cholesterol (mg/dL)
Low-density lipoprotein (LDL) cholesterol concentration was measured in mg/dL. The change from baseline to week 12 was evaluated.
Time frame: Baseline and week 12
Change in triglycerides (mg/dL)
High-density lipoprotein (HDL) cholesterol concentration was measured in mg/dL. The change from baseline to week 12 was evaluated.
Time frame: Baseline and week 12
Change in gastrointestinal symptoms (GSRS total score)
Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS), a 15-item questionnaire evaluating abdominal pain, reflux, indigestion, diarrhea, and constipation. Each item is scored from 1 (no discomfort) to 7 (very severe discomfort), resulting in a total score ranging from 15 to 105. Higher scores indicate greater severity of gastrointestinal symptoms and therefore a worse outcome. Changes in total scores from baseline to week 12 were evaluated.
Time frame: Baseline and week 12
Change in Bristol Stool Scale score
Stool consistency was assessed using the Bristol Stool Form Scale (BSFS), which classifies stool into seven types, ranging from Type 1 (separate hard lumps) to Type 7 (entirely liquid stool). Scores range from 1 to 7. Lower scores indicate harder stools, while higher scores indicate softer or more liquid stools. Types 3 and 4 are generally considered indicative of normal stool consistency. Therefore, higher scores do not necessarily indicate a better or worse outcome. Changes in stool consistency from baseline to week 12 were evaluated.
Time frame: Baseline and week 12
Change in Psychological Well-Being Scale total score
Psychological well-being was assessed using the Psychological Well-Being Scale (Flourishing Scale), developed by Diener et al. and adapted into Turkish by Telef. The scale consists of eight items rated on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). Total scores range from 8 to 56, with higher scores indicating greater psychological well-being and therefore a better outcome. Changes in total scores from baseline to week 12 were evaluated.
Time frame: Baseline and week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Sep 2024, 3 months.
Of 3,683 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 3 months is below that.
Counting every sponsor, half of 3,846 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.